Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rectal Neoplasms | 16 | 2022 | 1152 | 1.460 |
Why?
|
Pancreatic Neoplasms | 36 | 2023 | 5312 | 1.430 |
Why?
|
Adenocarcinoma | 33 | 2023 | 6312 | 1.420 |
Why?
|
Liver Neoplasms | 26 | 2021 | 4313 | 1.140 |
Why?
|
Neoadjuvant Therapy | 22 | 2023 | 2810 | 1.110 |
Why?
|
Fluorouracil | 29 | 2023 | 1621 | 1.000 |
Why?
|
Cholangiocarcinoma | 9 | 2024 | 546 | 0.870 |
Why?
|
Bile Duct Neoplasms | 9 | 2024 | 601 | 0.870 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 35 | 2023 | 11656 | 0.830 |
Why?
|
Carcinoma, Pancreatic Ductal | 11 | 2023 | 1708 | 0.830 |
Why?
|
Carcinoma, Hepatocellular | 17 | 2019 | 2295 | 0.790 |
Why?
|
Colorectal Neoplasms | 15 | 2022 | 6853 | 0.650 |
Why?
|
Anus Neoplasms | 6 | 2020 | 329 | 0.630 |
Why?
|
Hepatectomy | 7 | 2020 | 562 | 0.610 |
Why?
|
Yttrium Radioisotopes | 1 | 2017 | 107 | 0.540 |
Why?
|
Leucovorin | 12 | 2023 | 630 | 0.530 |
Why?
|
Deoxycytidine | 17 | 2018 | 860 | 0.520 |
Why?
|
Neuroendocrine Tumors | 7 | 2021 | 649 | 0.500 |
Why?
|
Gastrointestinal Neoplasms | 5 | 2023 | 951 | 0.450 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2021 | 734 | 0.440 |
Why?
|
Positron-Emission Tomography | 12 | 2022 | 6436 | 0.430 |
Why?
|
Radiopharmaceuticals | 6 | 2022 | 2630 | 0.420 |
Why?
|
Salvage Therapy | 2 | 2017 | 1265 | 0.400 |
Why?
|
Pancreatectomy | 5 | 2023 | 809 | 0.390 |
Why?
|
Organoplatinum Compounds | 9 | 2019 | 409 | 0.370 |
Why?
|
Embolization, Therapeutic | 2 | 2019 | 1412 | 0.370 |
Why?
|
Camptothecin | 7 | 2017 | 589 | 0.360 |
Why?
|
Neoplasm Staging | 26 | 2022 | 11125 | 0.360 |
Why?
|
Lymphopenia | 2 | 2024 | 280 | 0.350 |
Why?
|
Esophageal Neoplasms | 6 | 2020 | 1655 | 0.350 |
Why?
|
Stomach Neoplasms | 6 | 2020 | 1422 | 0.350 |
Why?
|
Survival Rate | 23 | 2024 | 12793 | 0.330 |
Why?
|
Antimetabolites, Antineoplastic | 7 | 2014 | 640 | 0.330 |
Why?
|
Antineoplastic Agents | 18 | 2020 | 13625 | 0.330 |
Why?
|
Aged | 87 | 2024 | 168615 | 0.290 |
Why?
|
Middle Aged | 94 | 2024 | 219628 | 0.290 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2011 | 380 | 0.280 |
Why?
|
Disease-Free Survival | 17 | 2017 | 6814 | 0.260 |
Why?
|
Adrenalectomy | 1 | 2008 | 348 | 0.260 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2008 | 255 | 0.260 |
Why?
|
Retrospective Studies | 44 | 2024 | 80125 | 0.250 |
Why?
|
Neoplasm, Residual | 3 | 2021 | 1007 | 0.250 |
Why?
|
Male | 101 | 2024 | 358602 | 0.250 |
Why?
|
Aged, 80 and over | 41 | 2024 | 58864 | 0.230 |
Why?
|
Treatment Outcome | 39 | 2023 | 64867 | 0.220 |
Why?
|
Gene Amplification | 2 | 2020 | 1085 | 0.220 |
Why?
|
Female | 96 | 2024 | 390174 | 0.220 |
Why?
|
Photons | 2 | 2019 | 580 | 0.210 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 87 | 0.200 |
Why?
|
Humans | 126 | 2024 | 759098 | 0.200 |
Why?
|
Antibodies, Monoclonal | 13 | 2015 | 9131 | 0.200 |
Why?
|
Chemoembolization, Therapeutic | 2 | 2013 | 129 | 0.200 |
Why?
|
Fluorodeoxyglucose F18 | 8 | 2022 | 2008 | 0.200 |
Why?
|
Kaplan-Meier Estimate | 13 | 2020 | 6530 | 0.200 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 224 | 0.200 |
Why?
|
Coronary Vasospasm | 1 | 2022 | 83 | 0.190 |
Why?
|
Pancreaticoduodenectomy | 4 | 2019 | 506 | 0.190 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2018 | 801 | 0.190 |
Why?
|
Quinazolines | 6 | 2014 | 1362 | 0.190 |
Why?
|
Radiodermatitis | 2 | 2019 | 59 | 0.190 |
Why?
|
Sirolimus | 4 | 2013 | 1537 | 0.190 |
Why?
|
Peritoneal Neoplasms | 2 | 2022 | 706 | 0.180 |
Why?
|
Adult | 61 | 2024 | 219353 | 0.180 |
Why?
|
Esophagogastric Junction | 2 | 2020 | 343 | 0.180 |
Why?
|
Biliary Tract Neoplasms | 2 | 2014 | 185 | 0.180 |
Why?
|
Radiotherapy Dosage | 11 | 2019 | 2895 | 0.180 |
Why?
|
Prognosis | 22 | 2024 | 29559 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2019 | 9271 | 0.170 |
Why?
|
Neuroblastoma | 1 | 2008 | 1252 | 0.170 |
Why?
|
Gallbladder Neoplasms | 2 | 2014 | 191 | 0.170 |
Why?
|
Radiotherapy | 4 | 2021 | 1503 | 0.160 |
Why?
|
Carcinoid Tumor | 2 | 2011 | 228 | 0.160 |
Why?
|
Mitomycin | 5 | 2019 | 262 | 0.160 |
Why?
|
Doxorubicin | 3 | 2013 | 2202 | 0.160 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 6 | 2015 | 1708 | 0.160 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2015 | 921 | 0.160 |
Why?
|
Intraoperative Care | 2 | 2019 | 768 | 0.150 |
Why?
|
Gastrinoma | 1 | 2017 | 20 | 0.150 |
Why?
|
Feasibility Studies | 4 | 2023 | 5192 | 0.150 |
Why?
|
Losartan | 1 | 2019 | 258 | 0.150 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4030 | 0.150 |
Why?
|
Pelvic Bones | 2 | 2017 | 271 | 0.140 |
Why?
|
Treatment Refusal | 1 | 2020 | 427 | 0.140 |
Why?
|
Liver Failure | 1 | 2019 | 248 | 0.140 |
Why?
|
DNA, Neoplasm | 2 | 2019 | 1744 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 9 | 2022 | 36164 | 0.140 |
Why?
|
Combined Modality Therapy | 12 | 2022 | 8548 | 0.140 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 424 | 0.130 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 721 | 0.130 |
Why?
|
Healthcare Disparities | 2 | 2023 | 3364 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2020 | 568 | 0.130 |
Why?
|
Laparotomy | 1 | 2018 | 468 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2022 | 3518 | 0.130 |
Why?
|
ras Proteins | 4 | 2014 | 1052 | 0.130 |
Why?
|
Colonic Neoplasms | 2 | 2020 | 2519 | 0.130 |
Why?
|
Lymph Nodes | 3 | 2019 | 3482 | 0.120 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 233 | 0.120 |
Why?
|
Mutation | 9 | 2020 | 29878 | 0.120 |
Why?
|
Rectum | 1 | 2019 | 896 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2019 | 5214 | 0.120 |
Why?
|
Neutropenia | 2 | 2017 | 885 | 0.120 |
Why?
|
Bile Ducts, Intrahepatic | 3 | 2014 | 298 | 0.120 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2015 | 332 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 3 | 2010 | 2047 | 0.110 |
Why?
|
Spermine | 1 | 2013 | 69 | 0.110 |
Why?
|
Follow-Up Studies | 14 | 2024 | 39213 | 0.110 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 1995 | 251 | 0.110 |
Why?
|
Survival Analysis | 12 | 2019 | 10181 | 0.110 |
Why?
|
Neoplasm Metastasis | 7 | 2020 | 4883 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 9 | 2021 | 20461 | 0.110 |
Why?
|
Dacarbazine | 2 | 2013 | 560 | 0.100 |
Why?
|
Capsules | 1 | 2013 | 192 | 0.100 |
Why?
|
Blood Vessels | 1 | 2018 | 1112 | 0.100 |
Why?
|
Tretinoin | 1 | 1995 | 522 | 0.100 |
Why?
|
Glutarates | 1 | 2014 | 244 | 0.100 |
Why?
|
Radiation Injuries | 2 | 2017 | 1183 | 0.100 |
Why?
|
Cisplatin | 4 | 2010 | 1643 | 0.100 |
Why?
|
Indoles | 2 | 2011 | 1828 | 0.100 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2014 | 423 | 0.100 |
Why?
|
beta Karyopherins | 1 | 2011 | 46 | 0.100 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 1659 | 0.090 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1101 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2019 | 2052 | 0.090 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2012 | 749 | 0.090 |
Why?
|
Medical Oncology | 2 | 2021 | 2309 | 0.090 |
Why?
|
Mesentery | 1 | 2011 | 203 | 0.090 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 933 | 0.090 |
Why?
|
Multimedia | 1 | 2010 | 74 | 0.090 |
Why?
|
Phenylurea Compounds | 1 | 2013 | 529 | 0.090 |
Why?
|
Thrombosis | 1 | 2023 | 3042 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2012 | 1785 | 0.080 |
Why?
|
Vagina | 1 | 2014 | 840 | 0.080 |
Why?
|
Arsenicals | 1 | 2009 | 116 | 0.080 |
Why?
|
Triazoles | 1 | 2014 | 904 | 0.080 |
Why?
|
Bone Marrow | 2 | 2017 | 2911 | 0.080 |
Why?
|
Drug Carriers | 1 | 2013 | 705 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 4 | 2014 | 4492 | 0.080 |
Why?
|
Carcinoembryonic Antigen | 2 | 2023 | 336 | 0.080 |
Why?
|
Lymphoma | 1 | 2017 | 1898 | 0.080 |
Why?
|
Radiosurgery | 1 | 2017 | 1341 | 0.070 |
Why?
|
Standard of Care | 2 | 2022 | 551 | 0.070 |
Why?
|
Tubulin | 1 | 2011 | 692 | 0.070 |
Why?
|
Quinolines | 1 | 2013 | 758 | 0.070 |
Why?
|
Disease Progression | 7 | 2022 | 13470 | 0.070 |
Why?
|
Proportional Hazards Models | 6 | 2020 | 12526 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3616 | 0.070 |
Why?
|
Anal Canal | 2 | 2020 | 373 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1649 | 0.070 |
Why?
|
Tumor Burden | 4 | 2017 | 1886 | 0.070 |
Why?
|
Chorioamnionitis | 1 | 2008 | 156 | 0.070 |
Why?
|
Glutathione | 1 | 2009 | 582 | 0.070 |
Why?
|
Radiography, Abdominal | 1 | 2010 | 532 | 0.070 |
Why?
|
Quality of Life | 3 | 2023 | 13285 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2008 | 369 | 0.060 |
Why?
|
Intestine, Small | 1 | 2012 | 1204 | 0.060 |
Why?
|
Radiology Information Systems | 1 | 2010 | 528 | 0.060 |
Why?
|
Catheter Ablation | 1 | 2019 | 2749 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4111 | 0.060 |
Why?
|
Colectomy | 1 | 2010 | 695 | 0.060 |
Why?
|
Prospective Studies | 10 | 2021 | 54190 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 2062 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5875 | 0.060 |
Why?
|
Lamivudine | 2 | 2022 | 363 | 0.060 |
Why?
|
Maximum Tolerated Dose | 3 | 2013 | 876 | 0.060 |
Why?
|
Propensity Score | 2 | 2023 | 1917 | 0.060 |
Why?
|
Patient-Centered Care | 1 | 2014 | 1414 | 0.060 |
Why?
|
Pain | 3 | 2014 | 5059 | 0.060 |
Why?
|
Pregnancy Trimester, First | 1 | 2008 | 907 | 0.060 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1190 | 0.050 |
Why?
|
Mesenteric Veins | 1 | 2023 | 82 | 0.050 |
Why?
|
Estradiol | 1 | 2010 | 1931 | 0.050 |
Why?
|
Adenomatous Polyposis Coli Protein | 2 | 2014 | 180 | 0.050 |
Why?
|
Lymphatic Metastasis | 3 | 2019 | 2943 | 0.050 |
Why?
|
Abortion, Spontaneous | 1 | 2008 | 529 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1135 | 0.050 |
Why?
|
Cohort Studies | 7 | 2023 | 41266 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2022 | 2925 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2020 | 2499 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 14648 | 0.050 |
Why?
|
Massachusetts | 4 | 2020 | 8788 | 0.050 |
Why?
|
Intestines | 1 | 2011 | 1905 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1612 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 160 | 0.050 |
Why?
|
Laparoscopy | 2 | 2019 | 2156 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2020 | 12152 | 0.050 |
Why?
|
Hepatitis B, Chronic | 1 | 2005 | 402 | 0.050 |
Why?
|
Fractals | 1 | 2021 | 128 | 0.050 |
Why?
|
Portal Vein | 1 | 2023 | 429 | 0.050 |
Why?
|
Nitrates | 1 | 2022 | 264 | 0.050 |
Why?
|
Drug Administration Schedule | 4 | 2013 | 4893 | 0.050 |
Why?
|
Physician-Patient Relations | 1 | 2014 | 3235 | 0.050 |
Why?
|
Cicatrix | 1 | 2006 | 781 | 0.050 |
Why?
|
GTP Phosphohydrolases | 2 | 2014 | 515 | 0.050 |
Why?
|
Carcinoma, Small Cell | 1 | 2003 | 416 | 0.040 |
Why?
|
Albumins | 1 | 2023 | 567 | 0.040 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2021 | 3761 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2021 | 237 | 0.040 |
Why?
|
Databases, Factual | 3 | 2019 | 8001 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 787 | 0.040 |
Why?
|
Nitrosourea Compounds | 1 | 1998 | 32 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2023 | 656 | 0.040 |
Why?
|
Biopsy | 1 | 2011 | 6770 | 0.040 |
Why?
|
Edema | 1 | 2023 | 772 | 0.040 |
Why?
|
Colostomy | 1 | 2019 | 105 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 690 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 705 | 0.040 |
Why?
|
Young Adult | 7 | 2020 | 58477 | 0.040 |
Why?
|
Carbon-Carbon Ligases | 1 | 1997 | 19 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2011 | 12963 | 0.040 |
Why?
|
Cytotoxins | 1 | 1998 | 153 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2008 | 4283 | 0.040 |
Why?
|
Prothrombin | 1 | 1997 | 191 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2010 | 3598 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 5790 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2003 | 937 | 0.030 |
Why?
|
Pelvis | 1 | 2020 | 742 | 0.030 |
Why?
|
Radiography | 3 | 2012 | 6964 | 0.030 |
Why?
|
Paclitaxel | 1 | 2023 | 1716 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1007 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 776 | 0.030 |
Why?
|
Radiation Dosage | 2 | 2017 | 1955 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2005 | 2635 | 0.030 |
Why?
|
Liver | 2 | 2014 | 7514 | 0.030 |
Why?
|
Treatment Failure | 2 | 2017 | 2641 | 0.030 |
Why?
|
Thrombin | 1 | 1997 | 593 | 0.030 |
Why?
|
Age Factors | 3 | 2023 | 18391 | 0.030 |
Why?
|
Vitamin K | 1 | 1997 | 321 | 0.030 |
Why?
|
Incidence | 3 | 2021 | 21344 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2013 | 6239 | 0.030 |
Why?
|
Spiral Cone-Beam Computed Tomography | 1 | 2015 | 34 | 0.030 |
Why?
|
Immunotherapy | 2 | 2021 | 4626 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
CA-19-9 Antigen | 1 | 2014 | 106 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2015 | 2801 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 165 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 22023 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 264 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2013 | 516 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1583 | 0.030 |
Why?
|
Intestine, Large | 1 | 2012 | 67 | 0.030 |
Why?
|
United States | 4 | 2023 | 72238 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2719 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2013 | 524 | 0.030 |
Why?
|
Glutamic Acid | 1 | 1997 | 1166 | 0.020 |
Why?
|
Administration, Oral | 2 | 2011 | 4037 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2014 | 2866 | 0.020 |
Why?
|
Length of Stay | 2 | 2019 | 6452 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2010 | 3476 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2013 | 878 | 0.020 |
Why?
|
Brachytherapy | 1 | 2019 | 1239 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 3 | 2015 | 5637 | 0.020 |
Why?
|
Genes, ras | 1 | 2014 | 654 | 0.020 |
Why?
|
GPI-Linked Proteins | 1 | 2013 | 468 | 0.020 |
Why?
|
Adolescent | 4 | 2023 | 87551 | 0.020 |
Why?
|
Hydroxyestrones | 1 | 2010 | 17 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15262 | 0.020 |
Why?
|
Genotype | 2 | 2017 | 12940 | 0.020 |
Why?
|
Time Factors | 4 | 2015 | 40083 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 2010 | 375 | 0.020 |
Why?
|
Urogenital System | 1 | 2010 | 88 | 0.020 |
Why?
|
Neoplasm Proteins | 2 | 2013 | 3614 | 0.020 |
Why?
|
Defecation | 1 | 2012 | 190 | 0.020 |
Why?
|
Lymphatic Irradiation | 1 | 2010 | 115 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3062 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 894 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 558 | 0.020 |
Why?
|
Diphosphonates | 1 | 2014 | 637 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2013 | 673 | 0.020 |
Why?
|
Failure to Thrive | 1 | 2009 | 140 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 129 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2013 | 2234 | 0.020 |
Why?
|
Risk Factors | 3 | 2014 | 74167 | 0.020 |
Why?
|
Patient Dropouts | 1 | 2010 | 412 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 1998 | 6490 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7235 | 0.020 |
Why?
|
Endoscopy, Digestive System | 1 | 2011 | 351 | 0.020 |
Why?
|
Cause of Death | 1 | 2019 | 3719 | 0.020 |
Why?
|
Cytarabine | 1 | 2010 | 696 | 0.020 |
Why?
|
Drug Substitution | 1 | 2010 | 296 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2011 | 549 | 0.020 |
Why?
|
Prescriptions | 1 | 2010 | 388 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2014 | 8489 | 0.020 |
Why?
|
Lung Neoplasms | 2 | 2003 | 13243 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2009 | 454 | 0.020 |
Why?
|
Intestinal Obstruction | 1 | 2011 | 436 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2014 | 7838 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5499 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2010 | 497 | 0.020 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1184 | 0.020 |
Why?
|
Nausea | 1 | 2009 | 675 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1648 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7247 | 0.020 |
Why?
|
Vomiting | 1 | 2009 | 646 | 0.020 |
Why?
|
Radiology Department, Hospital | 1 | 2010 | 405 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3890 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7790 | 0.020 |
Why?
|
Pregnancy | 1 | 2008 | 29650 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1296 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8530 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2011 | 2119 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5876 | 0.020 |
Why?
|
Postoperative Period | 1 | 2010 | 1823 | 0.020 |
Why?
|
Taxoids | 1 | 2009 | 668 | 0.020 |
Why?
|
Efficiency, Organizational | 1 | 2010 | 694 | 0.020 |
Why?
|
Diarrhea | 1 | 2012 | 1340 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2013 | 3618 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 2000 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2019 | 12383 | 0.020 |
Why?
|
Gastrointestinal Tract | 1 | 2010 | 830 | 0.010 |
Why?
|
Nurses | 1 | 2014 | 2466 | 0.010 |
Why?
|
Lymph Node Excision | 1 | 2010 | 1304 | 0.010 |
Why?
|
Disease Management | 1 | 2015 | 2495 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2852 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2013 | 15815 | 0.010 |
Why?
|
Piperidines | 1 | 2012 | 1648 | 0.010 |
Why?
|
Documentation | 1 | 2010 | 885 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14439 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2011 | 1132 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 1998 | 8050 | 0.010 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2005 | 618 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2019 | 4737 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2000 | 5247 | 0.010 |
Why?
|
Caregivers | 1 | 2014 | 2213 | 0.010 |
Why?
|
Hepatitis B virus | 1 | 2005 | 517 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20027 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 2006 | 881 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4041 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8435 | 0.010 |
Why?
|
Radiotherapy, High-Energy | 1 | 2000 | 228 | 0.010 |
Why?
|
Risk Assessment | 2 | 2013 | 24049 | 0.010 |
Why?
|
Logistic Models | 1 | 2014 | 13309 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 12871 | 0.010 |
Why?
|
Recurrence | 1 | 2011 | 8465 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2009 | 3201 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16878 | 0.010 |
Why?
|
Kringles | 1 | 1997 | 8 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10515 | 0.010 |
Why?
|
Palliative Care | 1 | 2013 | 3608 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9372 | 0.010 |
Why?
|
Virus Replication | 1 | 2005 | 2431 | 0.010 |
Why?
|
New England | 1 | 2000 | 1042 | 0.010 |
Why?
|
Signal Transduction | 2 | 2011 | 23328 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3523 | 0.010 |
Why?
|
Risk | 1 | 2008 | 9622 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15639 | 0.010 |
Why?
|
Disulfides | 1 | 1997 | 465 | 0.010 |
Why?
|
CHO Cells | 1 | 1997 | 1388 | 0.010 |
Why?
|
Comorbidity | 1 | 2009 | 10550 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2010 | 4356 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1997 | 1695 | 0.010 |
Why?
|
Cricetinae | 1 | 1997 | 2424 | 0.010 |
Why?
|
Pneumonectomy | 1 | 2000 | 1109 | 0.010 |
Why?
|
Protein Precursors | 1 | 1997 | 1135 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 10825 | 0.010 |
Why?
|
Contrast Media | 1 | 2006 | 5305 | 0.010 |
Why?
|
Animals | 2 | 2022 | 167531 | 0.010 |
Why?
|
Ultrasonography | 1 | 2005 | 5954 | 0.010 |
Why?
|
Hospitalization | 1 | 2011 | 10732 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2008 | 21992 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 1997 | 3729 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 17748 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1997 | 13439 | 0.000 |
Why?
|
Peptide Fragments | 1 | 1997 | 5100 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1997 | 17611 | 0.000 |
Why?
|